BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group and previously served...
BC Extra | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate of more than $600 million in follow-ons. Karuna Therapeutics Inc. (NASDAQ:KRTX) raised $250 million late Wednesday through the sale...
BC Week In Review | Feb 7, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BC Extra | Feb 4, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BC Week In Review | Dec 21, 2018
Company News

Otsuka's Avanir to terminate Onzetra license

OptiNose Inc. (NASDAQ:OPTN) said it received written notice from Avanir Pharmaceuticals Inc. that the latter intends to terminate, effective March 10, a license granting it rights to develop and commercialize migraine drug Onzetra Xsail in...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Jun 8, 2018
Financial News

Follow-on roundup: ImmunoGen, Mirati, Zymeworks, Viking, OptiNose

ImmunoGen Inc. (NASDAQ:IMGN), Mirati Therapeutics Inc. (NASDAQ:MRTX), Zymeworks Inc. (NYSE:ZYME; TSX:ZYME), Viking Therapeutics Inc. (NASDAQ:VKTX) and OptiNose Inc. (NASDAQ:OPTN) each priced follow-ons, raising a total of more than $465 million. ImmunoGen raised $150.7 million through...
BC Extra | Jun 7, 2018
Financial News

Follow-on roundup: ImmunoGen, Mirati, Zymeworks, Viking, OptiNose

ImmunoGen Inc. (NASDAQ:IMGN), Mirati Therapeutics Inc. (NASDAQ:MRTX), Zymeworks Inc. (NYSE:ZYME; TSX:ZYME), Viking Therapeutics Inc. (NASDAQ:VKTX) and OptiNose Inc. (NASDAQ:OPTN) each priced follow-ons, raising a total of more than $465 million. ImmunoGen raised $150.7 million through...
BioCentury | Jan 13, 2018
Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
BC Week In Review | Jan 5, 2018
Financial News

OptiNose draws down $75M in debt financing

Ear, nose and throat allergy company OptiNose Inc. (NASDAQ:OPTN) said on Jan. 2 it entered a $100 million debt financing agreement with Athyrium Capital Management. At close, $75 million in senior secured notes were issued....
Items per page:
1 - 10 of 16